Working… Menu

Study of Descartes-30 in Acute Respiratory Distress Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04524962
Recruitment Status : Recruiting
First Posted : August 24, 2020
Last Update Posted : February 10, 2021
Information provided by (Responsible Party):
Cartesian Therapeutics

Brief Summary:
Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19

Condition or disease Intervention/treatment Phase
Acute Respiratory Distress Syndrome Covid19 Biological: Descartes 30 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/IIA Study of Descartes-30 in Acute Respiratory Distress Syndrome
Actual Study Start Date : September 15, 2020
Estimated Primary Completion Date : September 25, 2021
Estimated Study Completion Date : September 25, 2022

Arm Intervention/treatment
Experimental: Descartes 30 Biological: Descartes 30
Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.

Primary Outcome Measures :
  1. To assess the safety of Descartes-30 in patients with moderate-to-severe ARDS. [ Time Frame: 2 years ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must be 18 years of age or older at the time of enrollment
  • Patient maintains a diagnosis of moderate or severe ARDS according to the Berlin definition of ARDS

Exclusion Criteria:

  • Patient is currently enrolled into another therapeutic clinical trial with an experimental therapy that has not received marketing approval by U.S. FDA.
  • Patient is in moribund state with expected survival <24 hours.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04524962

Layout table for location contacts
Contact: Adam S Chowdhury, MD, MBA 3026486497

Layout table for location information
United States, Alabama
University of Alabama at Birmingham Not yet recruiting
Birmingham, Alabama, United States, 35294-0007
Contact: Patrick Frazier         
Principal Investigator: Nathaniel Erdmann, MD         
Sub-Investigator: Amit Gaggar, MD         
United States, California
University of California-Irvine Not yet recruiting
Irvine, California, United States, 92697
Contact: Nour Alsharif         
Principal Investigator: Richard A Lee, MD         
United States, Iowa
University of Iowa Hospitals and Clinics Not yet recruiting
Iowa City, Iowa, United States, 52242
Contact: Kim Sprenger         
Principal Investigator: Alejandro Comellas, MD         
United States, Maryland
University of Maryland Medical Center Medical Center Not yet recruiting
Baltimore, Maryland, United States, 21201
Contact: Thelma Harrington         
Principal Investigator: Avelino Verceles, MD         
United States, Massachusetts
Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Mayra Pinilla Vera, MD         
Principal Investigator: Rebecca Baron, MD         
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Ryan Kennedy, MD         
Principal Investigator: Ryan Kennedy, MD         
Sponsors and Collaborators
Cartesian Therapeutics
Layout table for additonal information
Responsible Party: Cartesian Therapeutics Identifier: NCT04524962    
Other Study ID Numbers: DC30-1A
First Posted: August 24, 2020    Key Record Dates
Last Update Posted: February 10, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders
Infant, Premature, Diseases
Infant, Newborn, Diseases
Lung Injury